Physician profile
Thomas Murray Baker
NPI 1093756207
$6,591.34
in general payments reported to CMS, 2019-2025
37 companies · $978 in 2025
The $978 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $556 · 2021: $935 · 2022: $1,023 · 2023: $969 · 2024: $1,007 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,295.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $913.73 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $613.42 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $552.89 | 2021-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $542.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $377.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $338.72 | 2019-2024 | Verquvo, Belsomra, M-M-R II |
| Pfizer INC. | $288.12 | 2019-2025 | |
| Lilly USA, LLC | $186.00 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $162.71 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $159.02 | 2019-2024 | Belbuca, Xtampza |
| Novartis Pharmaceuticals Corporation | $147.64 | 2021-2025 | |
| Exact Sciences Corporation | $146.38 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.78 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $109.53 | 2021-2025 | Keveyis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $76.63 | 2019 | |
| Shield Therapeutics INC | $74.94 | 2023-2024 | Accrufer |
| Dexcom, INC. | $64.33 | 2023-2025 | Dexcom G6 Transmitter |
| Kci USA, INC. | $47.70 | 2020 | |
| Sanofi Pasteur INC. | $42.97 | 2019-2020 | |
| Inspire Medical Systems, INC. | $34.23 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $30.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.37 | 2024 | Rexulti |
| Acadia Pharmaceuticals INC | $20.72 | 2019 | |
| Genentech USA, INC. | $19.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.58 | 2022 | |
| Esperion Therapeutics, INC. | $18.67 | 2021 | |
| Boston Scientific Corporation | $17.66 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.28 | 2023 | |
| Viatris Specialty LLC | $15.61 | 2025 | Yupelri |
| Eisai INC. | $14.39 | 2020 | |
| Allergan, INC. | $12.33 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.11 | 2019 | |
| Shire North American Group INC | $11.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.61 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.